| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 人福医药集团股份公司成立于1993年，于1997年在上海证券交易所上市，是湖北省医药工业龙头企业、中国医药工业30强、国家技术创新示范企业、中国医药企业制剂国际化先导企业，已在国内的麻醉药品、甾体激素类药物、维吾尔民族药等多个细分领域建立了领导或领先地位。 公司以医药工业为主、医药商业为辅，稳步推进国际化。医药工业实现医药中间体-原料药-药用辅料-药物制剂全产业链的全剂型生产能力；医药商业坚持“医疗服务综合供应商”定位，布局商业网络，实现区域全覆盖；国际化形成了全球研发、注册、生产、销售的医药全价值链能力，已有80多个产品出口全球70多个国家和地区。 公司立足临床价值高的创新药、创新制剂和高端仿制药，瞄准前沿领域，打造一流的创新研发产业化平台。已在中国武汉、宜昌，美国新泽西、圣路易斯等地设立研发中心，汇聚医药研发人员1700余人，其中博士190余人，享受国务院特殊津贴专家7人。集团在研项目350多个，其中一类新药30余个，24个项目被列为国家重大新药创制项目，已获授权专利794项。 人福医药坚定“做医药细分市场领导者”的发展战略，通过“聚焦、创新、国际化”三大战略路径，逐步实现由国际跟跑、并跑到领跑的跨越，打造具有全球竞争力的国际一流医药企业。 | ||||||||||||||||||||||||
| Main Business | 医药、医疗器械、生殖健康等产品及技术的研发、生产、销售及技术服务；房地产开发及销售；供热设备产品的制造及销售。 | ||||||||||||||||||||||||
| Legal Representative | 李杰 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 李前伦 | ||||||||||||||||||||||||
| Solicitors | 北京市君泽君律师事务所 | ||||||||||||||||||||||||
| Auditors | 大信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 027-87597232 | ||||||||||||||||||||||||
| Fax No | 027-87596393 | ||||||||||||||||||||||||
| Website | www.humanwell.com.cn | ||||||||||||||||||||||||
| renfu.pr@renfu.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 06/06/1997 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.320 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.460 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 10.441 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 30.895B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |